Article

The aim was to investigate the use of cardioprotective drug therapies
(aspirin or other antiplatelet agents, beta-blockade,
renin-angiotensin-aldosterone-system-blockade (RAAS-blockade) and statins) and
treatment targets achieved in a large cohort of patients with established
coronary artery disease and diabetes across Europe. METHODS AND RESULTS: EUROASPIRE III is an observational cross-sectional study of stable coronary
artery disease patients aged 18-80 years from 76 centres in 22 European countries
conducted in 2006-2007. The glycaemic status (prevalent, incident or no
diabetes), the guideline treatment targets achieved and the use of
pharmacotherapies were assessed at one visit 6-36 months after the index event.
Of all 6588 patients investigated (women 25%), 4295 (65%) had no diabetes, 752
(11%) had incident diabetes and 1541 (23%) had prevalent diabetes. All four drugs
were used in 44% of the patients with no diabetes, 51% with incident diabetes and
50% with prevalent diabetes respectively. Individual prescriptions for patients
with no, incident and prevalent diabetes were respectively: aspirin or other
antiplatelet agents 91, 93, and 91%; beta-blockers: 81, 84, and 79%;
RAAS-blockers: 77, 76, and 68%; statins: 80, 80, and 79%. The proportion of
patients with coronary artery disease and prevalent diabetes reaching the
treatment targets were 20% for blood pressure, 53% for low density lipoprotein
cholesterol (LDL-cholesterol) and 22% for haemoglobin A1c (HbA1c). CONCLUSION:
This European study demonstrates a low use of cardioprotective drug therapies
among patients with a combination of coronary artery disease and diabetes, which
will be contributing to the poor achievement of risk factor treatment targets for
cardiovascular prevention.
CI - (c) The European Society of Cardiology 2014 Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav.

Langue : ANGLAIS